Clinical Perspectives of Theranostics |
| |
| Authors: | Shozo Okamoto Tohru Shiga Nagara Tamaki |
| |
| Institution: | 1.Department of Radiology, Obihiro-Kosei General Hospital, Obihiro 080-0024, Japan;2.Department of Diagnostic Radiology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan;3.Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima 960-1295, Japan;4.Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan |
| |
| Abstract: | Theranostics is a precision medicine which integrates diagnostic nuclear medicine and radionuclide therapy for various cancers throughout body using suitable tracers and treatment that target specific biological pathways or receptors. This review covers traditional theranostics for thyroid cancer and pheochromocytoma with radioiodine compounds. In addition, recent theranostics of radioimmunotherapy for non-Hodgkin lymphoma, and treatment of bone metastasis using bone seeking radiopharmaceuticals are described. Furthermore, new radiopharmaceuticals for prostatic cancer and pancreatic cancer have been added. Of particular, F-18 Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography (PET) is often used for treatment monitoring and estimating patient outcome. A recent clinical study highlighted the ability of alpha-radiotherapy with high linear energy transfer (LET) to overcome treatment resistance to beta--particle therapy. Theranostics will become an ever-increasing part of clinical nuclear medicine. |
| |
| Keywords: | PET theranostics radionuclide therapy cancer prognosis |
|
|
